Printer Friendly

BELMAC SUCCESSFULLY COMPLETES BIOLID(R) TWICE-A-DAY TABLET STUDY

 TAMPA, Fla., Oct ?/PRNewswire/ -- Belmac Corporation (AMEX: BLM) announced today that it has successfully completed its initial pilot study in the United States for the twice-a-day tablet formulation of Biolid(R), Belmac's patented advanced form of erythromycin. The study results support Biolid's(R) equivalency to the standard. Belmac will now continue to progress toward its goal of demonstrating superiority over existing erythromycin and cannot predict when phase III studies will commence.
 "We are very pleased with the Biolid(R) tablet results," commented Donald Boultbee, Belmac's president and chief executive officer. "We have completed a significant step toward making Biolid(R) a successful antibiotic in the market place."
 In other news, Belmac Corporation announced that Light Securities has transferred 865,100 shares of Belmac's common stock to Light Associates, Inc. In addition, Light Associates, Inc. has purchased an additional 291,300 shares in the open market, bringing its total holdings to 1,156,400 shares, or 6 percent of the total number of shares outstanding. Light Securities continues to hold 851,200 shares of Belmac common stock, or approximately 4.4 percent of the total number of shares outstanding.
 Belmac Corporation is an international pharmaceutical and health care corporation based in Tampa, Fla.
 -0- 10/15/93
 /CONTACT: Jill Figueredo or R. Stewart of Belmac, 813-286-4401/
 (BLM)


CO: Belmac Corporation ST: Florida IN: MTC SU:

AW-PC -- FL014 -- 2825 10/15/93 14:56 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 15, 1993
Words:233
Previous Article:COMCAST CORPORATION ANNOUNCES OFFERING OF $496.7 MILLION 1-1/8 PERCENT DISCOUNT CONVERTIBLE SUBORDINATED DEBENTURES DUE 2007
Next Article:AFRICAN DEVELOPMENT BANK SUBORDINATED BONDS RATED 'AA+' BY FITCH
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters